What is GRI's current stock price?

GRI (GRI Bio, Inc.) is currently trading at $2.06 with a market cap of $185.1K.

What sector is GRI Bio, Inc. in?

GRI Bio, Inc. (GRI) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

GRI GRI Bio, Inc.

Healthcare

$2.06-7.21%ClosedMarket Cap: $185,054

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.24

P/S

0.00

EV/EBITDA

0.99

DCF Value

$65.28

FCF Yield

-6559.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-199.5%

ROA

-96.2%

ROIC

-103.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-2.0M	$—
Q4 null	$0.00	$-2.7M	$—
Q4 2025	$0.00	$-2.7M	$-5.34
FY null	$0.00	$-12.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Ascendiant CapitalBuy

2026-03-11

Ascendiant CapitalBuy

2025-12-08

Ascendiant CapitalBuy

2025-09-22

HC Wainwright & Co.Buy

2025-06-11

Ascendiant CapitalBuy

2025-05-27

Trading Activity

Insider Trades

View All

Szekeres David Lesliedirector

SellMon Sep 22

SIMPSON CAMILLA Vdirector

SellMon Sep 22

Rongen Roelofdirector

SellMon Sep 22

Kelly Leanneofficer: Chief Financial Officer

SellMon Sep 22

Hertz Walter Marcdirector, officer: Chief Executive Officer

SellMon Sep 22

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-1.22

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Peers

ABP

INM